An observational study in Leg Ulcer, Diabetic Foot Ulcer and Pressure Ulcer, sponsored by BSN Medical GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-21.
Sponsored by BSN Medical GmbH · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Diabetic Foot with a site in Germany — 4 open to participants now, 4 under way, none of them phase 3. Diabetic Foot · Germany.
Among the 37 studies in Diabetic Foot with a site in Germany, this one is one of 2 that started in 2022, is one of 8 observational ones, and was the 30th registered.
1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.
Browse Diabetic Foot studies →4 of the 37 studies in Diabetic Foot with a site in Germany are open now. Recruiting first, the newest first:
Cutempa Medical AG · Sites in Germany
Ages 18+
Heinrich-Heine University, Duesseldorf · Sites in Germany
Ages 18+
VULM s.r.o. · Sites in Germany, Poland
Ages 18–85
Barbara Wolff-Winiski · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 11 · Phase 4 1
First in 2002; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 100 across 191 observational studies indexed under Diabetic Foot.
Median enrollment 136 across the 29 interventional studies, 89 across the 8 observational. Of the 29 that completed or were terminated, 11 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 37 have an industry lead sponsor. The 10 most frequent:
BSN Medical GmbH is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
BSN Medical GmbH has 1 study filed under Diabetic Foot — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 37 studies in Diabetic Foot with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a post - market study with a wound dressing, a CE-marked medical device available on the european market. The device will be used in routine clinical practice, i.e. within its intended purpose and without any additional invasive or stressing examinations for the patients.
Up to 36 adult patients with wounds suitable to be treated with the medical device and meeting the inclusion/exclusion criteria will be enrolled at two participating German sites.
During 5 on-site visits within 28 days routine weekly dressing changes the Health Care Professional will examine the wound and will perform required wound care and dressing changes. Pictures of the wound with and without dressing will be taken at each visit and used for automatic analysis. The subjects will be asked to rate their general wound pain and the pain perceived during dressing changes. A wound-related quality of life questionnaire will be presented to the subjects twice and the subject and HCP will rate their safisfaction with the product.
This Post Market Clinical Follow up (PMCF) study will examine product features of the CE-marked wound dressing after having received market authorization regarding the fulfilment of predefined requirements for the successful management of skin integrity during wound care. The primary purpose of this study is to evaluate clinical safety and performance of the product when used on several wounds in routine wound care without any additional invasive or burdensome methods and within the intended use.
As primary objective the dressing´s absorption performance and its ability to prevent exudate accumulation in the wound will be investigated. Further, device disintegration, need of debridement, wound and skin conditions, treatment related pain, general wound pain, dressing adhesion and quality of life as well as Helath Care professional's (HCP´s) and patient´s satisfaction are considered as secondary outcomes.
In total, 36 eligible subjects will be enrolled at 2 German sites, including 15 % dropouts.
5 on-site visits are to be performed by the subjects in the scope of routine weekly wound care/dressing change visits during 28 days (Day 0, Day7, Day 14, Day21, Day28). The IMD will be applied during each on-site visit including wound care, wound examination/documentation and dressing change according to HCP's judgment and individual circumstances of the wound. Photographic documentation of the wound and the wound with applied dressings will be performed and used for further automatic wound/tissue analyis. General wound pain as well as pain perceived during dressing change will be documented, as well as Wound-related Quality of life as well as Patient's/HCP's satisfaction with the product.
1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.
This study's enrollment of 36 is below the median of 100 across 191 observational studies indexed under Diabetic Foot.
Browse Diabetic Foot studies →BSN Medical GmbH is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Compared within Diabetic Foot, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leg Ulcer. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Representativeness of the investigation population is assumed to be high in relation to the target population since this is a PMCF study, where the IMD will be used within the intended purpose including the intended patient population. Therefore, the IMD will be tested by the population for whom it is in fact intended for once placed on the market among other intended users. Inclusion and exclusion criteria are aligned with the product´s intended purpose.
No vulnerable subjects such as children, pregnant women, or sponsors or manufacturers staff will participate in this study guaranteed by specific inclusion and exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
application of dressing
Exudate absorption by IMD ('yes', 'no')
Percentage of subjects with exudate absorbed by the IMD per visit
Time frame: day 7
Exudate absorption by IMD ('yes', 'no')
Percentage of subjects with exudate absorbed by the IMD per visit
Time frame: day 14
Exudate absorption by IMD ('yes', 'no')
Percentage of subjects with exudate absorbed by the IMD per visit
Time frame: day 21
Exudate absorption by IMD ('yes', 'no')
Percentage of subjects with exudate absorbed by the IMD per visit
Time frame: day 28
Exudate accumulation in the wound by IMD ( 'no', 'minimal amount', 'medium amount', 'high amount')
Percentage of subjects with remaining exudate in wound per amount and visit
Time frame: day 7
Exudate accumulation in the wound by IMD ( 'no', 'minimal amount', 'medium amount', 'high amount')
Percentage of subjects with remaining exudate in wound per amount and visit
Time frame: day 14
Exudate accumulation in the wound by IMD ( 'no', 'minimal amount', 'medium amount', 'high amount')
Percentage of subjects with remaining exudate in wound per amount and visit
Time frame: day 21
Exudate accumulation in the wound by IMD ( 'no', 'minimal amount', 'medium amount', 'high amount')
Percentage of subjects with remaining exudate in wound per amount and visit
Time frame: day 28
Changes in need for debridement
Percentage of subjects with need for debridement per visit
Time frame: Throughout days 0, 7, 14, 21 and 28
Changes in debridement ease
Percentage of subjects per debridement ease ('easy', 'moderate', 'heavy', 'not applicable') per visit
Time frame: Throughout days 0, 7, 14, 21 and 28
Changes in wound margin condition
Percentage of subjects per wound margin condition('intact', 'macerated', 'redness', 'ragged') per visit
Time frame: Throughout days 0, 7, 14, 21 and 28
Changes in peri-wound skin condition
Percentage of subjects per peri-wound skin condition ('intact', 'macerated', 'redness', 'dry/flaky', 'edematous' ,'weeping') per visit
Time frame: Throughout days 0, 7, 14, 21 and 28
Changes in wound tissue type
Percentage of subjects per wound tissue type ('epithelialization tissue', 'granulation tissue', 'slough', 'eschar/necrotic tissue', 'other') per visit
Time frame: Throughout days 0, 7, 14, 21 and 28
Ease of application
Percentage of subjects per ease of application ('very easy', 'easy', 'difficult', 'very difficult') per visit
Time frame: Throughout days 0, 7, 14, 21 and 28
Conformability during application
Percentage of subjects per conformability ('very good', 'good', 'poor', 'very poor') per visit
Time frame: Throughout days 0, 7, 14, 21 and 28
Ease of removal
Percentage of subjects per ease of removal ('very easy', 'easy', 'difficult', 'very difficult') per visit
Time frame: Throughout days 7, 14, 21 and 28
Dressing adherence on removal
Percentage of subjects per adherence ('none', 'minor', 'moderate', 'marked') per visit
Time frame: Throughout days 7, 14, 21 and 28
Pain on removal
Mean pain perceived by subject using a pain ruler (scale 0-10) per visit
Time frame: Throughout days 7, 14, 21 and 28
Changes in wound-pain
Mean pain perceived by subject using a pain ruler (scale 0-10) per visit
Time frame: Throughout days 7, 14, 21 and 28
Changes in Wound-quality of life Wound-QoL
percentage change in Wound-QoL total scores and subscale scores ('body', 'psyche', 'everyday life' and standalone item) between both visits
Time frame: Day 0 and Day 28
HCP Overall satisfaction
Percentage per HCP overall satisfaction category ('Very good', 'Good', 'Satisfactory', 'Sufficient', 'Insufficient') for final visit
Time frame: day 28
Subject Overall satisfaction
Percent of patient overall satisfaction category ('Very good', 'Good', 'Satisfactory', 'Sufficient', 'Insufficient') for all patients at visit 5
Time frame: day 28
Incidence of adverse events related to IMD
Total occurence of IMD related adverse events
Time frame: Throughout days 0, 7, 14, 21 and 28
Incidence of device disintegration (removability in one piece)
Total occurence of IMD disintegration during removal
Time frame: Throughout days 0, 7, 14, 21 and 28
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2022 to primary completion in Jul 2023, 15 months.
Of 90 observational studies under Diabetic Foot, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 59. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BSN Medical GmbH